<SEC-DOCUMENT>0001104659-12-026369.txt : 20120517
<SEC-HEADER>0001104659-12-026369.hdr.sgml : 20120517
<ACCEPTANCE-DATETIME>20120419103735
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-12-026369
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20120419

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="56%" valign="top" style="padding:0in 0in 0in 0in;width:56.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:5.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-weight:bold;"><img width="218" height="35" src="g18953bci001.jpg"></font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Avisheh   Avini </font></b><font size="2" style="font-size:10.0pt;">| 212 692 6200 | aavini@mintz.com</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.1%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chrysler Center</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">666 Third Avenue</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New York, NY 10017</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">212-935-3000</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">212-983-3115 fax</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">www.mintz.com</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">April&nbsp;19, 2012</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Via EDGAR and by Federal Express</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Securities and Exchange Commission<br> Division of Corporation Finance<br> 100 F Street, N.E.<br> Mail Stop 3561<br> Washington, D.C. 20549</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Re:</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="92%" valign="top" style="padding:0in 0in 0in 0in;width:92.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cyclacel Pharmaceuticals,&nbsp;Inc.</font></b></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="92%" valign="top" style="padding:0in 0in 0in 0in;width:92.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Revised Preliminary Proxy Statement on Schedule 14A</font></b></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="92%" valign="top" style="padding:0in 0in 0in 0in;width:92.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Filed on April&nbsp;17, 2012</font></b></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="92%" valign="top" style="padding:0in 0in 0in 0in;width:92.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">File No. 000-50626</font></b></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ladies and Gentleman:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On behalf of Cyclacel Pharmaceuticals,&nbsp;Inc. (the &#147;<b>Company</b>&#148;), we hereby file with the Securities and Exchange Commission (the <b>&#147;Commission&#148;</b>) a response to the oral comment provided by the staff (the &#147;<b>Staff</b>&#148;) of the Commission on April&nbsp;18, 2012, with regard to the Company&#146;s revised Preliminary Proxy Statement on Schedule 14A (File No.&nbsp;000-50626) as filed with the Commission on April&nbsp;17, 2012 (the &#147;<b>Proxy</b>  <b>Statement</b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">General</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">We note that you are seeking approval to effect a reverse stock split at a ratio of up to 10:1 to be determined by the board of directors. Please revise your disclosure to describe any specific plans, arrangements or understandings, whether written or oral, to issue any of the authorized shares that will be newly available as a result of the approval of the reverse stock split. If you have no such plans, arrangements or understandings, please revise your disclosure to so state.</font></b></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Response</font></u></i><font size="2" style="font-size:10.0pt;">:&#160;&#160; In response to the Staff&#146;s comment, the Company has revised its disclosure on page&nbsp;39 of the Proxy Statement so that the revised disclosure now reads as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;The proposed amendment to our Certificate of Incorporation to effect the Reverse Stock Split, as more fully described below, will effect the Reverse Stock Split but will not change the number of authorized shares of Common Stock or preferred stock, or the par value of Common Stock or preferred stock. Although the primary purpose of the proposed Reverse Stock Split is to enable the Company to regain compliance with the $1.00 per share minimum bid price for continued listing, the Board of Directors also considers it to be in the best interest of the Company to have a sufficient number of shares of Common Stock available for issuance in order to provide the Company with business and financing flexibility in the future.&nbsp; The Company does not, however, currently have any specific plans, arrangements or understandings relating to the issuance of any additional shares of authorized Common Stock that will become available following the Reverse Stock Split.&#148;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BOSTON | WASHINGTON | NEW YORK | STAMFORD | LOS ANGELES | PALO ALTO | SAN DIEGO | LONDON</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105948\12-1895-3\task5275772\1895-3-bc.htm',USER='105948',CD='Apr 19 19:37 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company hereby acknowledges that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Company is responsible for the adequacy and accuracy of the disclosure in its filings;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Staff comments or changes to disclosure to Staff comments do not foreclose the Commission from taking any action with respect to the filings; and</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Please call Jeffrey P. Schultz at (212) 692-6732 or the undersigned at (212) 692-6200 with any comments or questions and please send a copy of any written comments to the following parties:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Jeffrey P. Schultz,&nbsp;Esq.</font></b></p>
<p style="margin:0in 0in .0001pt 1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Avisheh Avini,&nbsp;Esq.</font></b></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">666 Third Avenue</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New York, NY 10017</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Phone: (212) 935-3000</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax: (212) 983-3115</font></p>
<p style="margin:0in 0in .0001pt 3.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="54%" valign="top" style="padding:0in 0in 0in 0in;width:54.28%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very   truly yours,</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="top" style="padding:0in 0in 0in 0in;width:54.28%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="top" style="padding:0in 0in 0in 0in;width:54.28%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.72%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">/s/ Avisheh   Avini</font></i></p>    </td>   </tr>
<tr>
<td width="54%" valign="top" style="padding:0in 0in 0in 0in;width:54.28%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Avisheh   Avini</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt 3.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 3.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">cc:</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Securities and Exchange Commission</font></u><font size="2" style="font-size:10.0pt;"> (Jeffrey P. Riedler,&nbsp;Esq., Assistant Director)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cyclacel Pharmaceuticals,&nbsp;Inc.</font></u><font size="2" style="font-size:10.0pt;"> (Spiro Rombotis, President and Chief Executive Officer; Paul McBarron, Chief Operating Officer, Chief Financial Officer and Executive Vice President, Finance)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_191911_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105948\12-1895-3\task5275772\1895-3-bc.htm',USER='105948',CD='Apr 19 19:37 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g18953bci001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g18953bci001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MP``+"``C`-H!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`/=[VY:SLI;A+::Y:,9$,`!=_89('ZURWAKXD:/XG\17
M>@V]MJ%IJ-JC/+#>0B,C:0".&//(KL:H:UJ]IH&BWFK7S,+:TB,LFT9)`[#W
M/05B^$_'-IXQB6XTW2M4CLFW;;NXA1(V(X('S$GGC@5U-%%%(KJQ8*P)4X.#
MT-+2%E7&2!GID]:4$$`@Y![T45Q?BOXDZ=X,D_XG&DZO';M)Y<=S'"C12'&>
M#OSTSU`Z&M_0=;_MZQ%XNFW]E$P5HQ>(J,ZD9!`#']<5JT44444444445\XZ
M\MWX9\97WQ'L]\D=IXAFL;V)>AAV(/URX^NVOH>RO+?4;&WO;202V]Q&LL3K
MT92,@UY?\6KB;Q!!?^&[61EM-.T^34]3D7U56,$7U9AN/LHK3^#T,.H?!S2;
M:>/?"Z31NN2,CS7STKE_`FB6EQ\7?%EE.UU+::6Z-9P274C)$2V<@%N>G>E^
M(6@ZOH_C;2;SP29X[U;>>^FM#<.T<_ELF0$)(R0Y&!C/UKT?P3XST_QMH*:A
M9GRYD^2ZMF/SP2=U/MZ'O^=<IKWA'37^*6@1!;A;.^@NYKJW6ZD5)73:5)`;
MU?M6U8?#?2Q>ZCJ.J--=7M[</*QCN98XXTZ(H56'10H)/)-<3X5T2SU#XO\`
MBW1KIKR73K&.,VT!O9L1D[<X^;/<UUFH_#=(]4;4-!NGM9&L+BUV7-Q+*J/(
M`JR*&)P0-V?7(J]8?#?PSI6F1P.EW(L*#=--?S`G`Y)PX`Z=@`*\]\.Z'!X^
M\=SWVEM>VG@_2V\H;;N4_;Y0<]V/R]/PQZ\>Y@`#`Z"O(/VC/^2?V/\`V$H_
M_1<E>K:=_P`@RT_ZXI_Z"*KZYI=GK&DSVE[&SPE2V%D9""!P05((KRGX,Z#8
M^)/`[WVL&\N[H7DD8D>]F!V@+@<.!W-=7;_#K2GU/5!%=SRZ1=1*A@%]*SV]
MRA8%D;=E>&Z9X(KG/@V&TS7?$WA[57EFUO3Y_P#CXFE=FE@.,$`DC&0#_P`#
M%=;\3FC;P@]HL)FU"]F2UT]%D9"+A\JK94@_*"S?\!HA\`:/8>$I-.F%Q<RB
M'=-=27,GF22JI^?.[(.2>!Q7(?!'2+36/`TVHZEY]W>3SRV[RS7$C$QX4;1S
MQ^%8=S=:S\.?B#KFK:8MU>>%K.:&WO;-IWE:%)(U<.NXG`!)P<]\'KFO;;.]
MTWQ+H:7-K*EUI]Y%PRDX92,$>H/8]Q7!^$/"^GVOQ(\4#-S)%ITEL;**2YD9
M8-\99L`MSD^N<5Z917F_A#2K3Q3X+\4V%X-UOJ.L7ZL<?=S)A2/<8!'N*Y;X
M9^-?^$.T;Q!X6\22%;KP^7D@4GF6//W$]?F(Q[./2NJET6YTSX2^)KW4P#K.
MJ65Q>7S?W7:,[8Q[(N%'T/K3O@:^_P"$^E#CY7F7_P`BL?ZUD_#_`/Y+5\0/
M]Z+^9KJ]38+\6/#P/5M,O`/^^HJYCQMX5U3PKKK^/?!<>;A>=4TU1\EU'U9@
M!W[G\QSG-O3/%FE^,_&7@_5=+ERC6E^LL3'YX7Q#E6'K_.O3*\D\$_\`)>?'
M7_7*+^2UZW7E/Q#UN^\5:]%\.?#<NV:<;]7NUY%O!W7/J01D>X'<X]&T/1;'
MP[HMKI.G0B*UMD"(.Y]23W).23ZFM"O(/VC/^2?V/_82C_\`1<E>K:=_R#+3
M_KBG_H(I]TZB"1"P#-&Q"YY.!S7BGP3\/7.I^`I9XO$6KV`^VRJ(K1XP@P%Y
MPR,<_C7IW@K0[SP]HDUC?3FYF^VW$HN';+S*\A8.W^T0>:X7XC`^"_B'X?\`
M'D*E;29O[/U/`X*'HQ_#/_?"UU=IM\3?$*6^!$FG:`AMX"#E7NI%!D8>NU"J
M_5VKJ[[_`(\+G_KDW\C7F?[/_P#R3,?]?TW_`++70^'HH;GQIXYAE1)8GGMD
M=&&0P-NN017$W,5]\%/$#7MJDUUX'U"7]_",LUA(>X]OYC@\@$]=X-OK74O'
M'C"]LKB.XM9_L+QRQG*L#">17=51U>358[$G1[>TGN\X"W<S1H!ZY56)[<8_
M&N1^'7A[Q/X4LGTS51I=Q;27$MPUS;SOO#/R1L*8//?(J/7?AE::U\3])\5N
M(_)MH]US$>LLJ8\H^_7G_<%;WC.RUS5-`NM+T6&P)O8)()9;N9D\H,,94*IW
M'!/<=!7._#OPUXK\$^'FT2YATF[@C,DL,L=U(K%FY"L#'TSGG]#57PQX1\7Z
M'X[UCQ%<1Z-+%K##SX([J0&$`\%28_F.,\<9]JT]6T;Q=<^/+#7[2#2/LNGQ
M36\<$MW('F20C+$B,A3\J\<].M=S&7,2&1560@;E4Y`/<`]ZX"S^&EOHOQ1B
M\5:.(H;2>&5+NVZ!78<,@]">H[=NO'=W37"6LC6D4<MP!\B22%%8^[`''Y&O
M-=`\)>,='^(&K^*)8M%E350$EMDNI`8@,8(8Q\G`]!U[5WVOC6&T6Y30?LHU
M)UVPO=,1&A/\1P#G'8>M<#X&\&^*_!5K>8M]%O\`4+V8S7-]+>2AY/0']V>!
MDGZDUM:VGQ&OM/EM-.C\/V+S*4-S]JF=XP>ZCRP,^F:ZS3+%=,TJSL$=G6VA
M2$.QR6V@#)/KQ7GGQ/\`!OBKQ[9QZ3:C2;33X;@3K-+<2-)(0I`RH3"_>/<]
MJV-.7XB6.F06LUMX;NI(8UC\W[3,F_`QDCRSS5&#1?'+ZY>Z]J$>B3WAM?L=
MC:QW,JPVZ,=SL28R68D)V'`ZC%4?`'A+QOX#T6;2D_L&^@>9IU+7$L;*Q`!'
M^K.1Q6\FG>,-6\2:9<:P=,L])L7:<P6-Q)(\\NTA-Q**-HR3CU`K5\:^'4\5
M^#]3T9@N^XA/DENBR#E#_P!]`4WP3X<7PIX0T[1^#+#'F=QSOE;ESGOR3^&*
MO:Z-5;2Y8]'@M);J0%/]*F:-%!!Y^56)YQQQ]:X[X:>%?$O@?0I=&O$TNZ@#
MR3Q30W#AMY`PI4ITR.N?P-6/#NC>+=+\7:SJMY!I#VNL31/)'%=2;[<(NSC,
M>'XQZ<BNTO;*VU&RFL[R!)[:9"DD4@RK*>H(KC/A[\/QX"O]>BMYA+IUY+')
E:[CET`#95OID8/<5W5%%%%%%%%%%%%%%%%%%%%%%%%%%%%?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
